50829 Köln, de
Thomas von Rüden
+49 (221) 8887-121
Direvo to collaborate with Medimmune on therapeutic protease for The treatment of Cns diseasesKöln, )
Under the terms of the agreement, Direvo will be applying its proprietary protein-engineering capabilities to create specifically engineered proteases. MedImmune will then be responsible for the development and marketing of the protease product that may arise under the agreement. Direvo will receive undisclosed upfront and milestone payments, as well as research funding plus royalties on potential sales of the therapeutic protease should it reach the market.
"We are very happy to partner this internally initiated research project. MedImmune is the perfect partner to ensure that this exciting novel class of therapeutics gets the expertise required for its successful development," said Dr. Thomas von Rüden, CEO of Direvo. "This collaboration is a further technical and commercial validation for Direvo's proven world-class technology-platform for the generation of optimized proteases as novel biopharmaceuticals. Beyond this, it demonstrates our ability to source internal projects that are of great interest to the pharmaceutical industry" he added.
Proteases are a class of powerful therapeutic agents already used in the treatment of a variety of conditions. They are naturally occurring enzymes responsible in the human body for proteolysis, the process by which proteins are cleaved and inactivated. Therapeutically, they can be engineered to selectively inactivate pathogenic agents such as tumor cells, viruses or bacteria.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.